세포 건강 스크리닝 시장 규모, 점유율, 동향 분석 보고서 : 검사 유형별, 검체 유형별, 채취 부위별, 지역별, 부문별 예측(2025-2033년)

Cellular Health Screening Market Summary

The global cellular health screening market size was estimated at USD 3.30 billion in 2024 and is projected to reach USD 7.41 billion by 2033, growing at a CAGR of 9.5% from 2025 to 2033. An aging global population and the prevalence of age-related chronic diseases drive the market growth. Over the projected period, the importance of precision medicine is expected to increase, driven by the need to analyze biomarkers for aging and overall cellular health.

The use of home diagnostic tests is significantly rising globally. The growing number of campaigns to educate the public about the signs of chronic diseases and how to prevent them in order to contain disease epidemics is expected to fuel the growth of the cellular health screening industry. As a result, there is a significant demand for cellular health screening kits and services, driven by increased patient awareness. Additionally, the use of these devices helps optimize prompt treatment decisions, increases the effectiveness of care provided, and dramatically lowers diagnostic costs, especially in resource-constrained countries with inadequate laboratory facilities.

Numerous studies have shown a connection between malignancies and telomere length. Telomere shortening as a tumor suppressor turns out to be a significant factor in cancer that has progressed more severely. Although it has been demonstrated that a range of variables, including infections, inflammation, and stress, affect the length of telomeres, inflammation causes oxidative stress, which, in turn, leads to telomere erosion. According to research, telomere maintenance plays a significant role in how aging and related disorders are affected by environmental, lifestyle, and genetic factors. As a result, it is crucial to understand how quickly telomeres change in order to comprehend biological aging and hereditary diseases. Furthermore, telomere length loss has been linked to pathologies associated with aging, including cancer, cardiovascular illnesses, and weakened immune systems. The need for cellular health screening is projected to increase over the years, driven by the rising incidence of chronic diseases, which in turn fuels the market.

Global Cellular Health Screening Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cellular health screening market report based on test type, sample type, collection site, and region:

• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Single Test Panels
  • Telomere Tests
  • Oxidative Stress Tests
  • Inflammation Tests
  • Heavy Metals Tests
• Multi Test Panels
• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
• Blood
• Saliva
• Serum
• Urine
• Collection Site Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Diagnostic Labs
• Offices
• Home
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Singapore
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Test Type
  • 1.2.2. Sample Type
  • 1.2.3. Collection Site
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Source
• 1.9. List of Primary Source
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Test Type Outlook
  • 2.2.2. Sample Type Outlook
  • 2.2.3. Collection Site Outlook
  • 2.2.4. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Cellular Health Screening Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Cellular Health Screening Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Cellular Health Screening Market: Test Type Estimates & Trend Analysis

• 4.1. Test Type Segment Dashboard
• 4.2. Cellular Health Screening Market: Test Type Movement Analysis
• 4.3. Global Cellular Health Screening Market Size & Trend Analysis, by Test Type, 2021 to 2033 (USD Million)
  • 4.3.1. Single Test Panels
    • 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.1.2. Telomere Tests
      • 4.3.1.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.1.3. Oxidative Stress Tests
      • 4.3.1.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.1.4. Inflammation Tests
      • 4.3.1.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.1.5. Heavy Metals Tests
      • 4.3.1.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.3.2. Multi-Test Panels
    • 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Cellular Health Screening Market: Sample Type Estimates & Trend Analysis

• 5.1. Sample Type Segment Dashboard
• 5.2. Cellular Health Screening Market: Sample Type Movement Analysis
• 5.3. Global Cellular Health Screening Market Size & Trend Analysis, by Sample Type, 2021 to 2033 (USD Million)
  • 5.3.1. Blood
    • 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.2. Saliva
    • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.3. Serum
    • 5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.3.4. Urine
    • 5.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Cellular Health Screening Market: Collection Site Estimates & Trend Analysis

• 6.1. Collection Site Segment Dashboard
• 6.2. Cellular Health Screening Market: Collection Site Movement Analysis
• 6.3. Global Cellular Health Screening Market Size & Trend Analysis, by Collection Site, 2021 to 2033 (USD Million)
  • 6.3.1. Hospitals
    • 6.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.2. Diagnostic Labs
    • 6.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.3. Offices
    • 6.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.3.4. Home
    • 6.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Cellular Health Screening Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2024 & 2033
• 7.3. Cellular Health Screening Market by Region: Key Takeaways
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Mexico
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Russia
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Russia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework/ reimbursement structure
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Regulatory framework/ reimbursement structure
    • 7.5.8.3. Competitive scenario
    • 7.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Regulatory framework/ reimbursement structure
    • 7.5.9.3. Competitive scenario
    • 7.5.9.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. China
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. India
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. Japan
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Singapore
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Singapore market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/ reimbursement structure
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.4. Kuwait
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Regulatory framework/ reimbursement structure
    • 7.8.4.3. Competitive scenario
    • 7.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. Life Length
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. SpectraCell Laboratories, Inc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. RepeatDx.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Cell Science Systems
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Quest Diagnostics Incorporated
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Laboratory Corporation of America Holdings
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. OPKO Health, Inc.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Genova Diagnostics (GDX)
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Immundiagnostik AG
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. DNA Labs India
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives